本文關(guān)鍵詞： GLP-1類似物 磺脲類 2型糖尿病 療效 安全性 系統(tǒng)評(píng)價(jià)　出處：《廣西醫(yī)科大學(xué)》2015年碩士論文　論文類型：學(xué)位論文

【摘要】：目的：系統(tǒng)評(píng)價(jià)GLP-1類似物與磺脲類對(duì)比在治療2型糖尿病的療效與安全。方法：計(jì)算機(jī)檢索PubMed、EMBASE、Cochrane Library databases、重慶維普數(shù)據(jù)庫、清華同方數(shù)據(jù)庫、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫、萬方數(shù)據(jù)庫,時(shí)間為截止至2015年3月2日。納入GLP-1類似物與磺脲類對(duì)比治療2型糖尿病患者的隨機(jī)對(duì)照試驗(yàn),采用Review Manager5.2軟件進(jìn)行meta分析。療效觀察指標(biāo)為：糖化血紅蛋白、空腹血糖、餐后2h血糖、體重、收縮壓,安全性觀察指標(biāo)為：低血糖事件、胃腸道不良反應(yīng)。結(jié)果：納入符合要求的13個(gè)隨機(jī)對(duì)照研究,共5100名患者,其中有7個(gè)研究均聯(lián)合了二甲雙胍治療進(jìn)行對(duì)比。Meta分析結(jié)果顯示,在療效方面：①降低糖化血紅蛋白方面,GLP-1類似物與磺脲類藥物對(duì)比無顯著差異,[SMD=-O.14,95%CI(-0.28,0.01),P=0.06]；進(jìn)行亞組分析提示無論是否聯(lián)合使用二甲雙胍,無論利拉魯肽還是其他種類GLP-1類似物與磺脲類對(duì)比均無顯著差異。②降低空腹血糖方面,GLP-1類似物與磺脲類對(duì)比無顯著差異,[SMD=-0.1,95%CI=(-0.27,-0.07),P=0.24]；進(jìn)行亞組分析提示無論是否聯(lián)合使用二甲雙胍,無論利拉魯肽還是其他種類GLP-1類似物與磺脲類對(duì)比均無顯著差異。③降低餐后2小時(shí)血糖方面,GLP-1類似物與磺脲對(duì)比無顯著差異,[SMD=-O.04,95%CI=(-0.13,-0.05), P=0.41]。④降低收縮壓方面,GLP-1類似物優(yōu)于磺脲類,[SMD=-O.22,95%CI=(-0.30,-0.15), P0.00001]。⑤減輕體重方面,GLP-1類似物優(yōu)于磺脲類,[SMD=-1.55, 95%CI=(-2.51,-0.59),P=0.001];進(jìn)行亞組分析提示無論是否聯(lián)合二甲雙胍治療、無論利拉魯肽還是其他種類GLP-1類似物均優(yōu)于磺脲類。⑥低血糖風(fēng)險(xiǎn),GLP-1類似物小于磺脲類,[RR=0.25,95%CI=(0.15,0.41), P 0.00001];進(jìn)行亞組分析提示無論是否聯(lián)合二甲雙胍治療、無論利拉魯肽還是其他種類GLP-1類似物低血糖風(fēng)險(xiǎn)均小于磺脲類。⑦胃腸道不良反應(yīng),GLP-1類似物較磺脲類明顯,[RR=2.10,95%CI=(1.34,3.29), P=0.001];進(jìn)行亞組分析提示當(dāng)單獨(dú)使用GLP-1類似物和磺脲類進(jìn)行對(duì)比時(shí),兩者胃腸道反應(yīng)物對(duì)比無顯著差異,當(dāng)均聯(lián)合使用二甲雙胍治療進(jìn)行對(duì)比時(shí),GLP-1類似物治療2型糖尿病胃腸道不良反應(yīng)較磺脲類明顯,利拉魯肽胃腸道不良反應(yīng)較磺脲類明顯。結(jié)論：對(duì)于2型糖尿病患者,GLP-1類似物與磺脲類降糖藥物對(duì)比,在療效方面,降低糖化血紅蛋白、空腹血糖及餐后2小時(shí)血糖無顯著差異,降低血壓及減輕體重更明顯。安全性方面,低血糖風(fēng)險(xiǎn)更低,當(dāng)聯(lián)合二甲雙胍治療時(shí),胃腸道不良反應(yīng)較明顯。
[Abstract]:Objective: to systematically evaluate the efficacy and safety of GLP-1 analogues and sulfonylureas in the treatment of type 2 diabetes mellitus. Methods: a computer-based search of PubMedus EMBASE Cochrane Library database, Chongqing Weip database, Tsinghua Tongfang database, Chinese biomedical literature database and Wanfang database was conducted. The time was up to March 2nd 2015. The randomized controlled trial of GLP-1 analogues and sulfonylureas in the treatment of type 2 diabetes mellitus was carried out with Review Manager5.2 software. The therapeutic effects were as follows: glycosylated hemoglobin, fasting blood glucose, 2 h postprandial blood glucose, body weight, systolic blood pressure and safety were observed as follows: hypoglycemia, gastrointestinal adverse reactions. Results: a total of 5100 patients were enrolled in 13 randomized controlled trials. Seven of the studies combined with metformin were compared with metformin therapy. Meta-analysis showed that, There was no significant difference between GLP-1 analogues and sulfonylurea drugs in reducing glycosylated hemoglobin. [SMD-O.149CI-0.28CI-0.06]; subgroup analysis showed that whether or not metformin was used in combination, There was no significant difference between GLP-1 analogues and sulfonylureas. 2 there was no significant difference between GLP-1 analogues and sulfonylureas in lowering fasting blood glucose. There was no significant difference between GLP-1 analogues and sulfonylureas. 3 there was no significant difference between GLP-1 analogues and sulfonylureas in reducing blood glucose at 2 hours after meal. [SMD-O.04C95CIK- 0.13- 0.05U, P0. 41] .4 GLP-1 analogues were superior to sulfonylurea in reducing systolic blood pressure (SBP). Ureas, [SMD-O.2295], [SMD-0.30U -0.15U, P0.00001] .5 GLP-1 analogues are superior to sulfonylureas in weight loss, [SMD-1.55, 95CIZ-2.51U -0.59Pn0.001]; subgroup analysis showed that whether or not combined with metformin, Both Lilaru peptide and other GLP-1 analogues were superior to sulfonylureas in hypoglycemia risk. GLP-1 analogue was less than sulfonylurea, [RRRN 0.25 ~ 95 CIQ 0.150.41, P 0.00001]. Subgroup analysis showed that whether combined with metformin or not, The hypoglycemic risk of both liraud and other GLP-1 analogues was lower than that of sulfonylurea .7 gastrointestinal adverse reactions. GLP-1 analogue was significantly higher than that of sulfonylurea. [RRRN 2.101095 CIQ 1.343.29, P0. 001]. The subgroup analysis showed that when compared with sulfonylurea alone, the subgroup analysis showed that the risk of hypoglycemia was lower than that of sulfonylurea. There was no significant difference in gastrointestinal reaction between the two groups. When both patients were treated with metformin, GLP-1 analogue was more effective than sulfonylurea in the treatment of type 2 diabetes mellitus. Conclusion: in comparison of GLP-1 analogue with sulfonylurea, glycosylated hemoglobin can be decreased in patients with type 2 diabetes mellitus. There was no significant difference in fasting blood glucose and 2 hours postprandial blood glucose, but it was more obvious to lower blood pressure and weight. In terms of safety, hypoglycemia risk was lower, and gastrointestinal adverse reactions were more obvious when combined with metformin.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R587.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 張德平;劉靜民;鄭秀瑗;;內(nèi)臟脂肪與血脂的關(guān)系及其對(duì)血脂異常的臨床預(yù)測(cè)價(jià)值[J];腸外與腸內(nèi)營養(yǎng);2012年05期

2 郭慶ul;;胰高糖素樣肽-1治療糖尿病所發(fā)生的胰腺炎的爭(zhēng)議[J];中國老年保健醫(yī)學(xué);2010年02期

3 周保安;;利拉魯肽與格列美脲治療2型糖尿病伴肥胖患者的療效比較[J];實(shí)用糖尿病雜志;2014年02期

4 樸金梅;李忠民;蔡知天;王春華;陳曉梅;陳秋麗;;長(zhǎng)春地區(qū)中老年人血脂水平與內(nèi)臟脂肪的關(guān)系[J];中國臨床康復(fù);2006年44期

5 黃海齊;蘭麗珍;孔慧平;;GLP-1類似物對(duì)糖尿病大鼠血脂的影響[J];中西醫(yī)結(jié)合心腦血管病雜志;2011年02期

6 綦雯雯;鐘歷勇;;胰高血糖素樣肽1類似物治療2型糖尿病的安全性與耐受性[J];藥品評(píng)價(jià);2011年02期

7 孫子林;;腸促胰素的心血管安全性再評(píng)價(jià)[J];藥品評(píng)價(jià);2014年15期

相關(guān)碩士學(xué)位論文 前1條

1 楊永超;GLP-1R激動(dòng)劑誘發(fā)大鼠胰腺組織病變機(jī)制的進(jìn)一步實(shí)驗(yàn)研究[D];中南大學(xué);2012年

，

本文編號(hào)：1485436